Harriet E Gee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1147948/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer. Cancer Research, 2011, 71, 5635-5645.	0.9	285
2	MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU. PLoS ONE, 2010, 5, e10345.	2.5	276
3	The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. British Journal of Cancer, 2011, 104, 1168-1177.	6.4	244
4	hsaâ€miRâ€210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer, 2010, 116, 2148-2158.	4.1	215
5	Programmed death ligand 1 expression in tripleâ€negative breast cancer is associated with tumourâ€infiltrating lymphocytes and improved outcome. Histopathology, 2016, 69, 25-34.	2.9	177
6	MicroRNA-10b and breast cancer metastasis. Nature, 2008, 455, E8-E9.	27.8	134
7	miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense. Cancer Research, 2018, 78, 501-515.	0.9	105
8	HypoxamiRs and Cancer: From Biology to Targeted Therapy. Antioxidants and Redox Signaling, 2014, 21, 1220-1238.	5.4	102
9	Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine, 2013, 91, 749-758.	3.9	64
10	Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. BMC Cancer, 2016, 16, 86.	2.6	51
11	Contouring consensus guidelines in breast cancer radiotherapy: Comparison and systematic review of patterns of failure. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 102-115.	1.8	28
12	<i>In vivo</i> dosimetric impact of breast tissue expanders on postâ€mastectomy radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 138-145.	1.8	27
13	Targeting Glucose Metabolism of Cancer Cells with Dichloroacetate to Radiosensitize High-Grade Gliomas. International Journal of Molecular Sciences, 2021, 22, 7265.	4.1	26
14	MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1104-1114.	0.8	18
15	A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2022, 113, 40-59.	0.8	14
16	Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Scientific Reports, 2020, 10, 10226.	3.3	10
17	Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis. Disease Markers, 2019, 2019, 1-12.	1.3	9
18	Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial. BMC Cancer, 2021, 21, 940.	2.6	5

HARRIET E GEE

#	Article	IF	CITATIONS
19	Impact of <scp>DNA</scp> damage response defects in cancer cells on response to immunotherapy and radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 546-559.	1.8	5
20	High-Risk Cutaneous Squamous Cell Carcinoma. Current Otorhinolaryngology Reports, 2018, 6, 120-128.	0.5	2
21	Radiation therapy in the prevention and management of brain metastases in patients with small cell lung cancer: a narrative review. Chinese Clinical Oncology, 2021, .	1.2	1
22	DIPG-17. IMPROVING THE RADIOSENSITIVITY OF DIFFUSE INTRINSIC PONTINE GLIOMAS BY MODULATING BIOENERGETIC PATHWAYS. Neuro-Oncology, 2019, 21, ii72-ii72.	1.2	0
23	Are signatures of radiosensitivity ready for routine clinical use? A pragmatic comparison of clinical, pathological, and gene signature predictors of outcome in oropharynx head and neck cancers Journal of Clinical Oncology, 2018, 36, e18046-e18046.	1.6	0
24	DIPG-13. TARGETING HYPOXIA AND MITOCHONDRIA WITH REPURPOSED METABOLIC DRUGS AS AN APPROACH TO RADIOSENSITIZATION FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG). Neuro-Oncology, 2020, 22, iii289-iii289.	1.2	0